BofA cuts BioNTech stock target from USD 122.00 to USD 114.00

Published on 10/20/2026 at 18:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 60.00 percent to EUR 105.60 million for quarter ended June 30. BioNTech stock cost EUR 80.08 at Lang & Schwarz on October 20, 2026.

Analyst target dated October 9, 2026

Bank of America cut its BioNTech target from USD 122.00 to USD 114.00 on October 9, 2026.
Revenue fell 60.00 percent to EUR 105.60 million in the second quarter of 2026.
BioNTech stock was trading at EUR 80.08 at Lang & Schwarz on October 20, 2026 at 6:38 p.m. CEST.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

Bank of America cut its BioNTech target from USD 122.00 to USD 114.00 on October 9, 2026, while maintaining a Buy rating, according to Markets Insider. BioNTech stock was trading at EUR 80.08 at Lang & Schwarz on October 20, 2026 at 6:38 p.m. CEST.

Quarterly revenue fell sharply

BioNTech reported revenue of EUR 105.60 million for the second quarter of 2026, down 60.00 percent from EUR 260.80 million in the year-earlier quarter. The company also posted a net loss per share of EUR 3.24, compared with a loss of EUR 1.60 in the prior-year period, according to The Globe and Mail.

Nasdaq range keeps the stock below its high

On Nasdaq, BioNTech was trading at USD 89.91 at 12:45 p.m. ET on October 20, 2026. The stock's 52-week range was USD 79.52 to USD 124.00, leaving the latest Nasdaq price 27.49 percent below the high. Market capitalization was USD 22.6 billion, and the trailing price-to-earnings ratio was negative 11.85.

Pipeline remains the valuation anchor

BioNTech describes itself as a biopharmaceutical company developing cancer therapies and other serious-disease treatments. Its investor page highlights immunomodulators, antibody drug conjugates and messenger RNA cancer immunotherapies in the oncology pipeline, alongside partnerships with Pfizer, Bristol Myers Squibb, Genentech and other companies, according to BioNTech.

The October 9 target reduction leaves Bank of America's USD 114.00 view 26.70 percent above the Nasdaq price of USD 89.91. That comparison places the analyst view alongside the recent earnings pressure rather than replacing it. BioNTech's next reported period will determine whether revenue begins to stabilize after the second-quarter decline.

Price and investor perspective

The euro quotation provides the German trading view, while the Nasdaq price supplies the company's home-market context. The current market picture combines a USD 22.6 billion valuation with a negative trailing price-to-earnings ratio and a 27.49 percent gap to the 52-week high.

The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.